$8.660
-0.856 (-9.89%)At close
MSLE Comparative Benchmarking
In the context of the broader market, MSLE competes directly with industry leaders such as ELDN and NMRA. With a market capitalization of $183.73M, it holds a significant position in the sector. When comparing efficiency, MSLE's gross margin of N/A stands against ELDN's N/A and NMRA's N/A. Such benchmarking helps identify whether Satellos Bioscience Inc. is trading at a premium or discount relative to its financial performance.
Satellos Bioscience Inc Financial Performance
Satellos has been experiencing significant net losses, with the latest reported net income of -11,718,000 USD for Q2 2026. The company has a current ratio of 11.22, indicating strong liquidity, but the overall financial health is challenged by ongoing losses.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.